GlassScriptPhysician profile
Bridgette J Pierre
NPI 1851727192
$5,365.04
in general payments reported to CMS, 2019-2025
27 companies · $85.44 in 2025
The $85.44 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,107 · 2022: $159 · 2024: $13.13 · 2025: $85.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $4,434.20 | 2021-2022 | |
| Janssen Biotech, INC. | $147.62 | 2021-2022 | |
| Pfizer INC. | $85.44 | 2025 | |
| Amgen INC. | $76.35 | 2021 | |
| Merck Sharp & Dohme LLC | $62.87 | 2021 | |
| Novartis Pharmaceuticals Corporation | $54.84 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $49.89 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $46.05 | 2021 | |
| Beigene USA, INC. | $36.43 | 2021 | |
| Incyte Corporation | $33.90 | 2021 | |
| Eisai INC. | $32.36 | 2021 | |
| Chiesi USA, INC. | $32.25 | 2021 | |
| Jazz Pharmaceuticals INC. | $27.63 | 2021 | |
| Morphosys, US INC. | $26.84 | 2021 | |
| Servier Pharmaceuticals LLC | $21.87 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.61 | 2021 | |
| Emmaus Medical, INC. | $19.74 | 2021 | |
| Acceleron Pharma, INC. | $18.75 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.47 | 2021 | |
| Astellas Pharma US INC | $16.32 | 2021 | |
| Karyopharm Therapeutics INC. | $16.09 | 2021 | |
| Dova Pharmaceuticals | $15.67 | 2021 | |
| Stemline Therapeutics INC. | $15.40 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.28 | 2021 | |
| Emd Serono, INC. | $14.85 | 2021 | |
| Genzyme Corporation | $13.19 | 2021 | |
| Array Biopharma INC | $13.13 | 2024 | Mektovi, Inlyta, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgette Pierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.